The European radiopharma sector gains momentum as Nuclidium AG closed a CHF 79 million ($99 million) Series B funding round, advancing clinical development of copper isotope-based diagnostics and therapeutics. Separately, Actithera A/S secured $75.5 million Series A to advance fibroblast activation protein (FAP)-targeted radiopharmaceutical candidates. Together, these financings underscore growing investor confidence in radiopharmaceuticals as a platform for precision oncology and diagnostic innovation, overcoming past production and supply limitations while enabling expanded global scaling and clinical testing.